Cassava Sciences was one of the fastest growing companies in the world last year after promising trials for its Alzheimer s drug. Now, experts are accusing it of potentially manipulating data.
Cassava Sciences is rangebound until results come for phase 3 clinical trials of simufilam for Alzheimer’s. What's the potential upside or downside? Find out.